Phase 2
Systemic Sclerosis ILD
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Detail

OPSUMIT® (macitentan) is an endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension. 

Study Purpose

Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension. This study aims to better understand patients with ILD-PH and scleroderma and to determine if treatment with Opsumit (aka Macitentan) is beneficial.

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >